Navigation Links
NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment

PSORENT Features a Unique and Innovative Formulation Available Without a

Prescription Through Physicians

PRINCETON, N.J., Feb. 4 /PRNewswire/ -- NeoStrata today announced the launch of PSORENT, a clinically proven, steroid-free, topical treatment for psoriasis. PSORENT contains LCD (liquid carbonis distillate), which has proven efficacy against psoriasis symptoms, in a novel, aesthetically advanced formulation and package that promotes high patient compliance. PSORENT is available without a prescription from dermatologists beginning March 2008.

"With the launch of PSORENT, physicians will be able to offer patients a novel psoriasis treatment that reduces the unpleasant aspects of traditional coal tar therapy, resulting in high patient compliance without compromising efficacy or safety," said Barbara Green, Vice President for Technology and Clinical Affairs at NeoStrata. "PSORENT's effective and unique fast-absorbing solution applies easily and conveniently making it an ideal first-line therapy for the vast majority of psoriasis patients."

PSORENT is an aesthetically advanced, fast absorbing topical coal tar solution that provides a new alternative for psoriasis patients and providers. Optimally formulated with a 15 percent concentration of LCD, the therapeutic equivalent of 2.3 percent coal tar, PSORENT is an innovative topical solution to treat the chronic redness and scaling associated with psoriasis. PSORENT is supplied in a convenient dab-on delivery system that speeds LCD absorption and avoids the stains, odor and mess that are typically associated with coal tar treatments. Additionally, the dab-on applicator allows the patient to apply PSORENT directly to the affected areas without touching either the solution or the skin, resulting in a highly effective and easy to use treatment. PSORENT is available only through physicians' offices. One 100mL bottle provides up to a 3-month supply, at a suggested retail price of $45.00, making it a cost effective alternative to prescription medications which may or may not be covered by health insurance.

Psoriasis is an immune-mediated, genetic disease manifesting in the skin and/or the joints. According to the National Institutes of Health, as many as 7.5 million Americans have psoriasis. The National Psoriasis Foundation defines mild psoriasis as affecting less than three percent of the body; three percent to 10 percent is considered moderate; more than 10 percent is considered severe. According to the National Psoriasis Foundation's Benchmark Survey on Psoriasis and Psoriatic Arthritis, the disease is not merely a cosmetic problem. Nearly 60 percent reported their psoriasis to be a large problem in their everyday life. The survey also indicates that psoriasis had a greater impact on quality of life in women and younger patients.

About NeoStrata

The NeoStrata Company, located in Princeton, NJ, develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the United States and internationally through physicians' offices, pharmacies and spas.

SOURCE The NeoStrata Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
Breaking Biology News(10 mins):